INDRAYANI BIOTECH LTD.

Indrayani Biotech Ltd has announced the closure of its trading window for directors, designated persons, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will be effective from October 01, 2026, until 48 hours after the declaration of the unaudited financial statements for the quarter and half-year ending September 30, 2026. The company has also updated this information on the NSDL portal to restrict trading by designated persons by freezing PAN at the security level. The exact date for the board meeting to declare these financial results will be intimated later.

Indrayani Biotech Ltd has announced a revised schedule for its partly paid-up Rights Issue. The Rights Issue Committee, in a meeting held on September 09, 2026, decided to open the issue on September 15, 2026, and close it on October 14, 2026. The last date for on-market renunciation has been set for October 08, 2026. This follows previous extensions and postponements of the issue. The revised Letter of Offer (LOF) and other related documents are available on the BSE website and the company's website.

Indrayani Biotech Limited has announced a Rights Issue of up to 3,25,25,897 partly paid-up Equity Shares at an issue price of ₹15 per share, aggregating up to ₹4878.88 Lakhs (₹48.79 Crores). The issue is on a rights basis to eligible equity shareholders in the ratio of 5 shares for every 7 fully paid-up shares held as of the record date, April 28, 2026. The issue price includes a premium of ₹5 per share. The company was originally incorporated in 1992 and later converted to a public limited company. The Rights Issue Committee has approved the Letter of Offer, which details the payment structure with ₹3.75 payable on application and ₹11.25 on subsequent calls. Investors are advised to review the risk factors before making investment decisions.

Indrayani Biotech Ltd has announced the resignation of Mr. K. Ravichandran as the Secretarial Auditor of the Company, effective August 6th, 2026. The resignation is due to personal reasons. The company will appoint a new Secretarial Auditor in due course to fill the vacancy. This disclosure is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indrayani Biotech Ltd has received approval from the Registrar of Companies (ROC), Chennai, for a two-month extension to hold its 34th Annual General Meeting (AGM) for the financial year 2025-26. The AGM, originally due by September 30, 2026, will now be held by November 30, 2026. The extension was granted due to ongoing capital restructuring plans, including a Rights Issue, which require multiple statutory and regulatory approvals. The exact date of the AGM within the extended period will be finalized by the Board of Directors.

Indrayani Biotech Ltd announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the standalone and consolidated results following a meeting held on August 17, 2026. The company has submitted the results as per SEBI regulations and will publish them on its website and the BSE website. The auditor's report includes a qualified opinion due to unconfirmed balances and differences in accounting standards for subsidiaries.

Indrayani Biotech Ltd announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results in a meeting held on August 17, 2026. The company will publish the results in newspapers and on its website, as well as on the BSE website. The auditors' report includes a qualified opinion due to uncertainties regarding trade receivables, loans, and the consolidation of subsidiaries based on Indian GAAP instead of IND AS.

Indrayani Biotech Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results during a meeting held on August 17, 2026. The company will publish the results in newspapers and on its website, as well as the BSE website. The auditor's report includes a qualified opinion due to uncertainties regarding confirmation and reconciliation of certain balances, and consolidation of subsidiaries under Indian GAAP instead of IND AS, with an unascertainable impact on the profit and loss account.

Indrayani Biotech Ltd has announced that its Board of Directors will convene on August 17, 2026. The primary agenda items include the consideration and approval of the audited financial statements for the quarter and financial year ended March 31, 2026. The board will also take on record the Auditors' Report on these financials and approve the Audited Financial Results for dissemination to the stock exchange, along with the text for newspaper advertisements. The meeting will also address any other business as permitted by the chair.

Indrayani Biotech Limited has received an order from the Goods and Services Tax Department revoking the cancellation of its GST registration. The cancellation, initially effective from April 28, 2026, due to non-filing of returns, has been reversed with effect from the same date. The revocation order was issued on July 15, 2026. The company has stated that this revocation has no impact on its operations. This update pertains to ongoing tax litigation and is disclosed as per SEBI LODR Regulations.